Table 5.

Impact of refeeding on mRNA content of major proteins involved in the regulation of liver de novo lipogenesis

	Control	DIO	DIOcit–stat
Srebf1	4.54 ± 0.95*	0.60 ± 0.09#, *	0.90 ± 0.09$
Lxrα	1.37 ± 0.17	0.98 ± 0.17	1.08 ± 0.13
Chrebp	0.84 ± 0.12	0.69 ± 0.07*	0.81 ± 0.07
PPAR α	0.33 ± 0.05*	0.53 ± 0.09*	0.46 ± 0.04*
Pgc‐1α	0.48 ± 0.05*	0.41 ± 0.07*	0.46 ± 0.10*
PPAR γ	0.96 ± 0.21	0.70 ± 0.14	0.86 ± 0.12
Fasn	2.96 ± 0.99*	1.07 ± 0.08#	2.18 ± 0.32*
Acc1	3.03 ± 0.93*	1.12 ± 0.21	1.61 ± 0.27 *
Scd1	0.48 ± 0.07*	0.81 ± 0.23	1.03 ± 0.34
Gpam	1.30 ± 0.07	0.84 ± 0.08#	0.75 ± 0.03#*
eNOS	0.89 ± 0.15	1.10 ± 0.10	1.14 ± 0.22

Hprt, hypoxanthine guanine phosphoribosyl transferase; Pgc‐1α, peroxisome proliferator‐activated receptor gamma coactivator 1‐α.

Results are expressed relative to fasted values (mean ± SEM; n = 5 to 7 samples per group). Dietary interventions: standard diet (control), high fat–high sucrose diet (DIO) and DIO enriched in citrulline (2.5 g∙kg⁻¹ body weight) and atorvastatin (10 mg∙kg⁻¹ body weight) (DIOcit–stat).

^* P < 0.05, significantly different from fasted values;

^$ P < 0.05, significantly different from control and DIO;

^# P < 0.05, significantly different from control.